What was the overall market valuation for the asthma and COPD drugs market in 2024?

The overall market valuation was $1767.5 Million in 2024. Read More

What is the projected market valuation for the asthma and COPD drugs market by 2035?

The projected market valuation for 2035 is $2490.0 Million. Read More

What is the expected CAGR for the asthma and COPD drugs market during the forecast period 2025 - 2035?

The expected CAGR for the market during the forecast period 2025 - 2035 is 3.17%. Read More

Which drug class had the highest valuation in 2024?

Combination drugs had the highest valuation at $800.0 Million in 2024. Read More

What are the projected valuations for bronchodilators in 2035?

The projected valuations for bronchodilators in 2035 are expected to range from $500.0 Million to $700.0 Million. Read More

Which route of administration is anticipated to dominate the market by 2035?

Inhalation is anticipated to dominate the market, with projected valuations between $800.0 Million and $1100.0 Million. Read More

What was the valuation for chronic obstructive pulmonary disease drugs in 2024?

The valuation for chronic obstructive pulmonary disease drugs was $600.0 Million in 2024. Read More

How does the valuation for pediatric patients compare to adult patients in 2024?

In 2024, the valuation for pediatric patients was $300.0 Million, significantly lower than the $1060.0 Million for adult patients. Read More

Which key players are leading the asthma and COPD drugs market?

Key players include GlaxoSmithKline, Boehringer Ingelheim, AstraZeneca, and Novartis. Read More

What is the expected valuation range for leukotriene modifiers in 2035?

The expected valuation range for leukotriene modifiers in 2035 is between $267.5 Million and $390.0 Million. Read More

Germany Asthma COPD Drugs Market

ID: MRFR/Pharma/47718-HCR

200 Pages

Satyendra Maurya

Last Updated: April 06, 2026

Germany Asthma COPD Drugs Market Research Report By Drug Class (Bronchodilators, Corticosteroids, Combination Drugs, Leukotriene Modifiers), By Route of Administration (Inhalation, Oral, Injection, Nasal), By Application (Asthma, Chronic Obstructive Pulmonary Disease, Allergic Rhinitis, Pulmonary Hypertension) and By Patient Group (Adult, Pediatric, Geriatric) - Growth & Industry Forecast 2025 To 2035

Germany Asthma COPD Drugs Market Infographic

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Chemicals and Materials, BY Drug Class (USD Million)
  1. 4.1.1 Bronchodilators
  2. 4.1.2 Corticosteroids
  3. 4.1.3 Combination Drugs
  4. 4.1.4 Leukotriene Modifiers
2. 4.2 Chemicals and Materials, BY Route of Administration (USD Million)
  1. 4.2.1 Inhalation
  2. 4.2.2 Oral
  3. 4.2.3 Injection
  4. 4.2.4 Nasal
3. 4.3 Chemicals and Materials, BY Application (USD Million)
  1. 4.3.1 Asthma
  2. 4.3.2 Chronic Obstructive Pulmonary Disease
  3. 4.3.3 Allergic Rhinitis
  4. 4.3.4 Pulmonary Hypertension
4. 4.4 Chemicals and Materials, BY Patient Group (USD Million)
  1. 4.4.1 Adult
  2. 4.4.2 Pediatric
  3. 4.4.3 Geriatric
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Chemicals and Materials
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Chemicals and Materials
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 GlaxoSmithKline (GB)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Boehringer Ingelheim (DE)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 AstraZeneca (GB)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Novartis (CH)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Teva Pharmaceutical Industries (IL)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Merck & Co. (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Sanofi (FR)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Roche (CH)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Mylan (US)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 GERMANY MARKET ANALYSIS BY DRUG CLASS
3. 6.3 GERMANY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
4. 6.4 GERMANY MARKET ANALYSIS BY APPLICATION
5. 6.5 GERMANY MARKET ANALYSIS BY PATIENT GROUP
6. 6.6 KEY BUYING CRITERIA OF CHEMICALS AND MATERIALS
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF CHEMICALS AND MATERIALS
9. 6.9 DRIVERS IMPACT ANALYSIS: CHEMICALS AND MATERIALS
10. 6.10 RESTRAINTS IMPACT ANALYSIS: CHEMICALS AND MATERIALS
11. 6.11 SUPPLY / VALUE CHAIN: CHEMICALS AND MATERIALS
12. 6.12 CHEMICALS AND MATERIALS, BY DRUG CLASS, 2024 (% SHARE)
13. 6.13 CHEMICALS AND MATERIALS, BY DRUG CLASS, 2024 TO 2035 (USD Million)
14. 6.14 CHEMICALS AND MATERIALS, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
15. 6.15 CHEMICALS AND MATERIALS, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Million)
16. 6.16 CHEMICALS AND MATERIALS, BY APPLICATION, 2024 (% SHARE)
17. 6.17 CHEMICALS AND MATERIALS, BY APPLICATION, 2024 TO 2035 (USD Million)
18. 6.18 CHEMICALS AND MATERIALS, BY PATIENT GROUP, 2024 (% SHARE)
19. 6.19 CHEMICALS AND MATERIALS, BY PATIENT GROUP, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 Germany MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY DRUG CLASS, 2025-2035 (USD Million)
  2. 7.2.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  3. 7.2.3 BY APPLICATION, 2025-2035 (USD Million)
  4. 7.2.4 BY PATIENT GROUP, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

Germany Chemicals and Materials Market Segmentation

Chemicals and Materials By Drug Class (USD Million, 2025-2035)

Bronchodilators
Corticosteroids
Combination Drugs
Leukotriene Modifiers

Chemicals and Materials By Route of Administration (USD Million, 2025-2035)

Inhalation
Oral
Injection
Nasal

Chemicals and Materials By Application (USD Million, 2025-2035)

Asthma
Chronic Obstructive Pulmonary Disease
Allergic Rhinitis
Pulmonary Hypertension

Chemicals and Materials By Patient Group (USD Million, 2025-2035)

Adult
Pediatric
Geriatric

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”